| Pharmacokineticparameters |
Units |
Intravenous |
Intramuscular |
| β |
/h |
0.020±0.001 |
0.019±0.001 |
| t1/2β |
h |
8.63±0.130 |
17.77±0.058 |
| AUC0-∞ |
γ•η/μΛ |
12.65±0.208 |
19.66±0.216 |
| AUMC |
μγ•η2/μΛ |
207.6±0.50 |
414.4±12.70 |
| Vdarea |
L/kg |
9.83±0.172 |
-- |
| Vdss |
L/kg |
2.99±0.038 |
-- |
| ClB |
L/kg/h |
0.187±0.002 |
-- |
| MRT |
h |
15.57±0.531 |
21.07±0.478 |
| MAT |
h |
-- |
7.618±0.549 |
| Cmax |
γ/μΛ |
-- |
1.76±0.010 |
| Tmax |
h |
-- |
1.00±0.00 |
| F |
% |
-- |
155.5±2.487 |
|
| Key: β: Elimination rate constant; t1/2 β: Elimination half-life; AUC0-∞: Area under
the curve from zero to infinity; AUMC: Area under first of moment curve; Vdarea:
Apparent volume of distribution; Vdss: Volume of distribution at steady state; ClB:
Total body clearance; MRT: Mean residence time; MAT: Mean absorption time;
Cmax: Maximum drug concentration; Tmax: Time to peak plasma drug concentration;
F: Bioavailability. |
| Table 2: Mean ± SE plasma pharmacokinetic parameters of orbifloxacin in goats
(n=6) following intravenous intramuscular administration at a dose rate 2.5 mg/kg
body weight. |
